Skip to main content

Advertisement

SpringerLink
Log in

Clinical features and treatment outcomes of lymphoplasmacytic lymphoma: a single center experience in Korea

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Lymphoplasmacytic lymphoma (LPL) constitutes less than 5% of all non-Hodgkin lymphomas, and little is known about clinical features and treatment outcomes for patients with LPL in East Asia. In this study, we summarize our experiences managing patients diagnosed with LPL in Korea. A retrospective analysis was performed using data for 22 patients with LPL diagnosed at Samsung Medical Center. LPL was more common among males (77.3%), with a median age of diagnosis of 63 years (range 26-86). The most common presenting symptom was fatigue related to anemia (59.1%), and the bone marrow was commonly involved at diagnosis (90.9%). IgM paraproteinemia was found in 15 patients, and only one patient had anti-hepatitis C virus. Although some patients could be observed without treatment, the majority of patients required systemic treatment. Chlorambucil alone and cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) or CHOP-like combination chemotherapy was frequently used as a first-line treatment, and a fludarabine-based regimen was commonly used as salvage therapy. However, responses to those treatments were not satisfactory. Even patients who could be monitored without therapy became refractory to salvage therapies once their disease progressed. Eight patients died due to disease progression, and the median overall survival was 70.8 months (95% CI: 31.4-109.2 months). This study describes the clinical features and treatment outcome of LPL in Korea. The treatment approach was too heterogeneous to draw firm conclusions, however, and treatment recommendations in the future should utilize a uniform treatment strategy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of tumors of hematopoietic and lymphoid tissues. IARC press, Lyon, pp 194–195

    Google Scholar 

  2. Treon SP, Dimopoulos MKyle RA (2003) Defining Waldenstrom's macroglobulinemia. Semin Oncol 30:107–9

    Article  PubMed  Google Scholar 

  3. Dimopoulos MA, Kyle RA, Anagnostopoulos A et al (2005) Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol 23:1564–77

    Article  PubMed  Google Scholar 

  4. Papamichael D, Norton AJ, Foran JM et al (1999) Immunocytoma: a retrospective analysis from St Bartholomew's Hospital-1972 to 1996. J Clin Oncol 17:2847–53

    CAS  PubMed  Google Scholar 

  5. Herrinton LJWeiss NS (1993) Incidence of Waldenstrom's macroglobulinemia. Blood 82:3148–50

    Google Scholar 

  6. Groves FD, Travis LB, Devesa SS et al (1998) Waldenstrom's macroglobulinemia: incidence patterns in the United States, 1988-1994. Cancer 82:1078–81

    Article  CAS  PubMed  Google Scholar 

  7. Ohshima K, Suzumiya J, Sato K et al (1999) B-cell lymphoma of 708 cases in Japan: incidence rates and clinical prognosis according to the REAL classification. Cancer Lett 135:73–81

    Article  CAS  PubMed  Google Scholar 

  8. Haddadin WJ (2005) Malignant lymphoma in Jordan: a retrospective analysis of 347 cases according to the World Health Organization classification. Ann Saudi Med 25:398–403

    PubMed  Google Scholar 

  9. Treon SP, Gertz MA, Dimopoulos M et al (2006) Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood 107:3442–6

    Article  CAS  PubMed  Google Scholar 

  10. Ko YH, Kim CW, Park CS et al (1998) REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer 83:806–12

    Article  CAS  PubMed  Google Scholar 

  11. Vitolo U, Ferreri AJMontoto S (2008) Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia. Crit Rev Oncol Hematol 67:172–85

    Article  PubMed  Google Scholar 

  12. Mele A, Pulsoni A, Bianco E et al (2003) Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood 102:996–9

    Article  CAS  PubMed  Google Scholar 

  13. Takeshita M, Sakai H, Okamura S et al (2006) Prevalence of hepatitis C virus infection in cases of B-cell lymphoma in Japan. Histopathology 48:189–98

    Article  CAS  PubMed  Google Scholar 

  14. Singh A, Eckardt KU, Zimmermann A et al (1993) Increased plasma viscosity as a reason for inappropriate erythropoietin formation. J Clin Invest 91:251–6

    Article  CAS  PubMed  Google Scholar 

  15. Garcia-Sanz R, Montoto S, Torrequebrada A et al (2001) Waldenstrom macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol 115:575–82

    Article  CAS  PubMed  Google Scholar 

  16. Dimopoulos MA, Kastritis E, Delimpassi S et al (2008) The international prognostic scoring system for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens. Haematologica 93:1420–2

    Article  CAS  PubMed  Google Scholar 

  17. O'Brien ME, Easterbrook P, Powell J et al (1991) The natural history of low grade non-Hodgkin's lymphoma and the impact of a no initial treatment policy on survival. Q J Med 80:651–60

    PubMed  Google Scholar 

  18. Kyle RA, Treon SP, Alexanian R et al (2003) Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30:116–20

    Article  PubMed  Google Scholar 

  19. Dhodapkar MV, Jacobson JL, Gertz MA et al (2001) Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood 98:41–8

    Article  CAS  PubMed  Google Scholar 

  20. Buske C, Hoster E, Dreyling M et al (2009) The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 23:153–61

    Article  CAS  PubMed  Google Scholar 

  21. Dimopoulos MA, Gertz MA, Kastritis E et al (2009) Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol 27:120–6

    Article  PubMed  Google Scholar 

  22. Coleman M, Leonard J, Lyons L et al (2003) Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. Semin Oncol 30:270–4

    Article  CAS  PubMed  Google Scholar 

  23. Treon SP, Hunter ZR, Matous J et al (2007) Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res 13:3320–5

    Article  CAS  PubMed  Google Scholar 

  24. Gilleece MH, Pearce R, Linch DC et al (2008) The outcome of haemopoietic stem cell transplantation in the treatment of lymphoplasmacytic lymphoma in the UK: a British Society Bone Marrow Transplantation study. Hematology 13:119–27

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by the Samsung Medical Center Clinical Research Development Program grant, #CRS-109-03-1.

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-Dong, Gangnam-Gu, Seoul, 135-710, South Korea

    Young-Woong Won, Seok Jin Kim, Kihyun Kim & Won Seog Kim

  2. Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

    Young Hyeh Ko

Authors
  1. Young-Woong Won
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seok Jin Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kihyun Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Young Hyeh Ko
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Won Seog Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Seok Jin Kim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Won, YW., Kim, S.J., Kim, K. et al. Clinical features and treatment outcomes of lymphoplasmacytic lymphoma: a single center experience in Korea. Ann Hematol 89, 1011–1018 (2010). https://doi.org/10.1007/s00277-010-0978-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-010-0978-1

Keywords

Search

Navigation